Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Laura Simon-Pearson"'
Autor:
Jessica D'Antonio, Laura Simon-Pearson, Terry Goldberg, Joel R Sneed, Sara Rushia, Nancy Kerner, Howard Andrews, Caroline Hellegers, Sierra Tolbert, Elena Perea, Jeffrey Petrella, Murali Doraiswamy, Davangere Devanand
Publikováno v:
BMJ Open, Vol 9, Iss 8 (2019)
Introduction Mild cognitive impairment (MCI) is common in older adults and represents a high-risk group for progression to Alzheimer’s disease (AD). Medication trials in MCI have generally failed, but new discoveries with brain plasticity in ageing
Externí odkaz:
https://doaj.org/article/40b72e8dc85245d090c62c95f286785f
Autor:
Laura Simon-Pearson, Elizabeth Crocco, Nadia Imran, Edward D. Huey, Mustafa M. Husain, Seonjoo Lee, Devangere P. Devanand, Gregory H. Pelton, Brent P. Forester, Deborah A. Deliyannides, Howard Andrews, Luminita Luca, Ipsit V. Vahia
Publikováno v:
Am J Geriatr Psychiatry
BACKGROUND: A case series suggested efficacy for lithium to treat agitation in dementia, but no placebo-controlled trials have been conducted. OBJECTIVES: To evaluate low-dose lithium treatment of agitation in Alzheimer’s disease (AD). METHOD: In a
Autor:
Joel R. Sneed, Jessica D’Antonio, Howard Andrews, Caroline Hellegers, Sara N. Rushia, Laura Simon-Pearson, Nancy Allison Kerner, Terry E. Goldberg, Elena Perea, Jeffrey R. Petrella, Sierra Tolbert, P. Murali Doraiswamy, Devangere P. Devanand
Publikováno v:
BMJ Open, Vol 9, Iss 8 (2019)
IntroductionMild cognitive impairment (MCI) is common in older adults and represents a high-risk group for progression to Alzheimer’s disease (AD). Medication trials in MCI have generally failed, but new discoveries with brain plasticity in ageing
Autor:
Jessica D'Antonio, Laura Simon-Pearson, Terry Goldberg, Joel R Sneed, Sara Rushia, Nancy Kerner, Caroline Hellegers, Sierra Tolbert, Elena Perea, Jeffrey Petrella, Murali Doraiswamy, Davangere Devanand
Publikováno v:
BMJ Open, Vol 9, Iss 8 (2019)
BMJ Open
BMJ Open
ObjectivesTo examine variation in outcomes, outcome measurement instruments (OMIs) and measurement times in clinical trials of non-valvular atrial fibrillation (NVAF) and to identify outcomes for prioritisation in developing a core outcome set (COS)
Autor:
Cynthia A. Munro, Lillian Lourenco, Paul A. Rosenberg, Anne Shanklin Casper, Laurie M. Ryan, Constantine Frangakis, Constantine G. Lyketsos, Maurcio Becerra, Paul B. Rosenberg, Hochang Lee, Davangere P. Devanand, Liberty Teodoro, Stephan Ehrhardt, Asa Widman, Alvin D. McKelvy, Gregory Pelton Jacobo Mintzer, Milap A. Nowrangi, Dave Shade, Sonia Pawluczyk, Anton P. Porsteinsson, Anthony Awkar, Arthur Williams, Zahinoor Ismail, Benoit H. Mulsant, Andy Lears, Lon S. Schneider, Sarah Lawrence, Kyle Lago, Jamie Perin, Melanie Keltz, Laura Simon-Pearson, David M. Shade, Lea T. Drye, Jacobo Mintzer, Jennifer Jones, Olga Brawman-Mintzer, Nicholas Bienko, Devangere P. Devanand, Tarek K. Rajji, Sheriza N. Baksh, Karen S. Dagerman, Susan Salem-Spencer, Kim Martin, Nimra Jamil, Meghan Schultz, Sheriza Baksh, Kaitlyn Lane, Dimitri Avramopoulos, Sanjeev Kumar, Nancy Kowalski, Bruce G. Pollock
Publikováno v:
Alzheimers Dement
Introduction Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation is one of the most common and distressing symptoms for patients with AD. Escitalopram for agitation in Alzheimer's disease (S-CitAD) tests a novel, clinical